Psilocybin

Experimental Psychiatry. V - Psilocybine, a New Psychotogenic Drug

This open-label study (n=4; 1960) with psilocybin (5-10mg) describes the subjective effects of the participants. The effects found range from slower speech to trying to stay in control (overcontrol). The participants didn't experience hallucinations and only one participants' pupils dilated.

Authors

  • Atwell, C. R.
  • Brown, J.
  • DiMascio, A.

Published

New England Journal of Medicine
individual Study

Abstract

From the first paragraph: Psilocybine, the phosphoric ester of 4-hydroxytryptamine has been established by [Albert] Hofmann et al. as the active principle of the Mexican mushroom family Psilocybe mexicana Heim. The chemists emphasize the fact that this chemical is the only phosphorylated indole compound that is known to occur in nature and that it is remarkable in that it is an indole substituted at the fourth position.

Unlocked with Blossom Pro

Research Summary of 'Experimental Psychiatry. V - Psilocybine, a New Psychotogenic Drug'

Study Details

Your Library